2021, Cilt 19, Sayı 2, Sayfa(lar) 177-184 |
|
Evaluation of Serum Oxidant and Antioxidant Levels in Axial Spondyloarthritis |
Kenan Güçlü1, Mehmet Okçu2, Senem Şaş3, Fatmanur Aybala Koçak4 |
1Kırsehir Ahi Evran University Faculty of Medicine, Department of Biochemistry, Kırsehir, Türkiye 2Marmara University Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Istanbul, Türkiye 3Erciyes University Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Kayseri, Türkiye 4Kırsehir Ahi Evran University Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Kırsehir, Türkiye |
Keywords: Axial spondyloarthritis; Ankylosing spondylitis; Oxidative stress |
|
Aim: To evaluate the relationship between serum oxidant-antioxidant levels and the duration of the
illness, disease activity and treatment modality in patients with axial spondyloarthritis (axSpA).
Material and Methods: Fourty two patients with axSpA and 20 healthy controls were included in this
cross-sectional study. To evaluate the serum oxidant-antioxidant levels of the patients, total antioxidant
status (TAS), total oxidant status (TOS) and oxidative stress index (OSI) levels were measured. Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index
(BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), ASQoL (Ankylosing Spondylitis Quality of
Life Index) scores, chest expansion, and number of enthesitis were recorded.
Results: No difference was observed in terms of demographic characteristics, laboratory findings,
serum TOS and TAS levels between the patient and control groups (p> 0.05). The TOS and TAS
concentrations did not differ between patients treated with biological agents and those treated with
conventional agents; and did not differ between cases of active (BASDAI ≥4) and inactive axSpA (p>
0.05). Only the TAS levels were found to be higher in patients with axSpA whose disease duration is >1
year than patients with disease duration ≤1 year (p <0.05); but there was no significant difference
between the TOS and OSI levels in terms of disease duration. No correlation was found between
laboratory and clinic parameters.
Conclusion: Serum oxidant and antioxidant levels may not be the guiding parameters in the treatment
and follow-up of axSpA disease. |
Top
Abstract
|
|
|